Case-based lecture: Pre-Myelofibrosis & Myelofibrosis

ESH eLearning, Paola Guglielmelli, 348278

Case-based lecture : Polycythemia Vera

ESH eLearning, Naseema Gangat, 348277

Case-based Lecture: Essential Thrombocythemia

ESH eLearning, Alberto Alvarez, 348276

Interactive case: MPN risk stratification

ESH eLearning, Francesco Passamonti, 348275

Panel discussion

ESH eLearning, Faculty / Presenters, 348274

Interactive CML case: Double trouble

ESH eLearning, Peter Westerweel, 348273

Case-based lecture: Salvage treatment and other lines

ESH eLearning, Gianantonio Rosti, 348272

Case-based lecture: The use of imatinib generics in the CML therapy

ESH eLearning, Tomasz Sacha, 348271

Case-based lecture: First line TKIs

ESH eLearning, Giuseppe Saglio, 348270

Interactive case

ESH eLearning, Francois-Xavier Mahon, 348269

Panel discussion

ESH eLearning, Faculty / Presenters, 348268

Brief oral Communication: Addition of Parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with Myelofibrosis

ESH eLearning, Abdulraheem Yacoub, 348267

Interactive case: Hepcidin Agonists in Polycythemia Vera

ESH eLearning, Marina Kremyanskaya, 348266

Case-based lecture: use of ruxolitinib in essential Thrombocythemia and Splanchnic vessel thrombosis

ESH eLearning, Brady L. Stein, 348265

Case-based lecture: Hydroxyurea / Resistance to Hydroxyurea

ESH eLearning, Alessandro Vannucchi, 348263

Interactive case

ESH eLearning, Jean-Jacques Kiladjian, 348262

Panel Discussion

ESH eLearning, Faculty / Presenters, 348261

MDS/CMML with TET2 or IDH mutations are associated with Systemic Inflammatory and Autoimmune Diseases and T-cell dysregulation

ESH eLearning, Lin-Pierre Zhao, 348260

Panel Discussion

ESH eLearning, Faculty / Presenters, 348259

How to target CHIP?

ESH eLearning, Klaus Metzeler, 348258

Current MDS/CMML clinical trials in Europe

ESH eLearning, Valeria Santini, 348255

Panel Discussion

ESH eLearning, Faculty / Presenters, 348254

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase Ib Study

ESH eLearning, Andrew Brunner, 348253

Novel strategies to treat cytopenia in Low Risk MDS

ESH eLearning, Uwe Platzbecker, 348252

Management of HMA failure

ESH eLearning, Valeria Santini, 348251

Strategies to improve HMA based therapy

ESH eLearning, Pierre Fenaux, 348250

Higher risk MDS: Lessons from elderly AML A renewed role for intensive chemotherapy (CPX 351…)?

ESH eLearning, Lionel ADES, 348249

Panel Discussion

ESH eLearning, Faculty / Presenters, 348248

Current treatment guidelines for CMML and rare subtypes

ESH eLearning, Raphael Itzykson, 348247

HMAs: When and how

ESH eLearning, Mikkael A. Sekeres, 348246

ESA and other growth factors

ESH eLearning, Valeria Santini, 348245

Overview of MDS treatment

ESH eLearning, Eva Hellström- Lindberg, 348244

Specific Subtypes of MDS, based on Morphology and Molecular Biology

ESH eLearning, Faculty / Presenters, 348243

Specific Subtypes of MDS, based on Morphology and Molecular Biology

ESH eLearning, Klaus Geissler, 348242

Specific Subtypes of MDS, based on Morphology and Molecular Biology

ESH eLearning, Aristoteles Giagounidis, 348241

Specific Subtypes of MDS, based on Morphology and Molecular Biology

ESH eLearning, Eric Solary, 348240

Panel Discussion

ESH eLearning, Faculty / Presenters, 348239

DEBATE: IS NGS useful in MDS? - No

ESH eLearning, Guillermo Sanz, 348238

Roundtable: Response criteria (with recent proposed changes, IWG 2018)

ESH eLearning, Pierre Fenaux, 348237

Role of comorbidities and quality of life in prognosis. New evaluation scales (QUALMS…)

ESH eLearning, Reinhard Stauder, 348236

Examining prognostic indicators in MDS

ESH eLearning, Michael Pfeilstöcker, 348235

Controversial debate: Genetics versus epigenetics in myeloid disease - Chair

ESH eLearning, Uwe Platzbecker, 348232

Panel Discussion

ESH eLearning, Faculty / Presenters, 348231

Immunological mess in MDS; is there a target?

ESH eLearning, Shahram Kordasti, 348230

Bone biology and the osteo-hematopoietic niche

ESH eLearning, Ulrike Baschant, 348229

Panel Discussion

ESH eLearning, Faculty / Presenters, 348228

Druggable molecular targets in MDS and elderly AML) (IDH, TP53…)

ESH eLearning, Torsten Haferlach, 348227

Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML

ESH eLearning, Oliver Kosmider, 348226

Panel Discussion

ESH eLearning, Faculty / Presenters, 348225

Relationships between inherited and acquired predisposition

ESH eLearning, Jaroslaw Maciejewski, 348224

Therapy related MDS and other environmental factors in MDS

ESH eLearning, Maria Teresa Voso, 348223

General discussion

ESH eLearning, Faculty / Presenters, 347827

Time limited vs continuous treatments

ESH eLearning, Barbara Eichhorst, 347826

Sequential vs combination treatments

ESH eLearning, William Wierda, 347825

MRD as a dynamic endpoint

ESH eLearning, Peter Hillmen, 347824

General discussion

ESH eLearning, Faculty / Presenters, 347823

Venetoclax

ESH eLearning, J.F. Seymour, 347821

PI3K

ESH eLearning, Jennifer R. Brown, 347820

Clonal evolution

ESH eLearning, Davide Rossi, 347819

General discussion

ESH eLearning, Faculty / Presenters, 347818

Gastroenterology

ESH eLearning, Stefano Fagiuoli, 347817

Infectious diseases

ESH eLearning, Michele Bartoletti, 347816

Dermatologist

ESH eLearning, Nicole Le, 347815

Cardiologist

ESH eLearning, Javid Moslehi, 347814

General discussion

ESH eLearning, Faculty / Presenters, 347813

CAR-T cells

ESH eLearning, Stephan Schuster, 347812

Novel inhibitors at preclinical level (MCL1 &CDK inhibitors)

ESH eLearning, Alexey Danilov, 347811

Next generation PI3K inhibitors

ESH eLearning, Peter Hillmen, 347810

General discussion

ESH eLearning, Faculty / Presenters, 347809

Immunomodulatory effects of kinase inhibitors

ESH eLearning, Adrian Wiestner, 347808

Role of T cells

ESH eLearning, Arnon Kater, 347807

General discussion

ESH eLearning, Faculty / Presenters, 347806

Short Oral Communication Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in CLL: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)

ESH eLearning, Julia Von, 347805

Venetoclax/PI3K real world

ESH eLearning, Lindsey Roeker, 347804

Ibrutinib real world

ESH eLearning, Loïc Ysebaert, 347803

Ibrutinib trials

ESH eLearning, Alessandra Tedeschi, 347802

General discussion

ESH eLearning, Faculty / Presenters, 347801

MURANO and MRD

ESH eLearning, J.F. Seymour, 347799

Ibrutinib for a small subgroup only

ESH eLearning, Florence Cymbalista, 347798

Ibrutinib for everybody

ESH eLearning, Jennifer Woyach, 347797

General discussion

ESH eLearning, Faculty / Presenters, 347796

Next generation BTK inhibitors (covalent/non-covalent?)

ESH eLearning, Anthony Mato, 347795

The latest news of stereotypes

ESH eLearning, Kostas Stamatopoulos, 347794

General discussion

ESH eLearning, Faculty / Presenters, 347793

Risk stratification in CLL

ESH eLearning, Antonio Cuneo, 347792

Ibrutinib resistance

ESH eLearning, Jennifer Woyach, 347791

Genetic predisposition

ESH eLearning, Jennifer R. Brown, 347790

Discussion

ESH eLearning, Faculty / Presenters, 336807

Genetic predisposition for myeloid malignancies: clinical management

ESH eLearning, Lucy Godley, 336806

Genetic editing of haematopoietic stem cells. Are we getting there?

ESH eLearning, Matthew Porteus, 336805

Discussion

ESH eLearning, Faculty / Presenters, 336804

Novel complement inhibitors

ESH eLearning, Antonio Maria Risitano, 336803

Discussion

ESH eLearning, Faculty / Presenters, 336802

How to handle moderate aplastic anaemia

ESH eLearning, Britta Höchsmann, 336801

Transplantation for acquired SAA: are we making progress?

ESH eLearning, Andrea Bacigalupo, 336800

Discussion

ESH eLearning, Faculty / Presenters, 336799

Selected brief oral communication: The Metabolomic Status of the Differentiating Myeloid Lineage in MDS with Low and High Bone Marrow Blast Counts.

ESH eLearning, Aikaterini Poulaki, 336798

Health-related quality of life and its assessment in aplastic anaemia and paroxysmal nocturnal haemoglobinuria

ESH eLearning, Jens Panse, 336797

Impact of clonal haematopoiesis in aplastic anaemia

ESH eLearning, Jaroslaw Maciejewski, 336796

Innate immunity and clonal evolution in bone marrow failure

ESH eLearning, Alan List, 336795